History of hematopoietic cell transplantation: challenges and progress

After more than 60 years of research in allogeneic hematopoietic cell transplantation (HCT), this therapy has advanced from one that was declared dead in the 1960s to a standard treatment of otherwise fatal malignant and non-malignant blood diseases. To date, close to 1.5 million hematopoietic cell transplants have been performed in more than 1,500 transplantation centers worldwide. This review will highlight the enormous efforts by numerous investigators throughout the world who have brought the experimental field of HCT to clinical reality, examine ongoing challenges, and provide insights for the future.

[1]  Chiung-Yu Huang,et al.  Impact of Polypharmacy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Older Adults. , 2021, Transplantation and cellular therapy.

[2]  H. Deeg,et al.  Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation , 2020, Cancers.

[3]  S. Tu,et al.  Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. , 2020, The Lancet. Oncology.

[4]  R. Storb,et al.  Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B-cell Malignancies. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  M. Mohty,et al.  Review of conditioning regimens for haplo-identical donor transplants using post-transplant cyclophosphamide in recipients of G-CSF mobilised peripheral stem cell. , 2020, Cancer treatment reviews.

[6]  P. Hari,et al.  Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades , 2020, Haematologica.

[7]  M. Carrington,et al.  Role of HLA-DP Expression in Graft-Versus-Host Disease After Unrelated Donor Transplantation. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. He,et al.  Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. , 2020, Blood advances.

[9]  M. Biernacki,et al.  T cell optimization for graft-versus-leukemia responses. , 2020, JCI insight.

[10]  M. Aljurf,et al.  Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT) , 2020, Bone Marrow Transplantation.

[11]  H. Einsele,et al.  How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. , 2020, Blood.

[12]  K. Ahn,et al.  Higher Total Body Irradiation (TBI) Dose-Intensity in Fludarabine (Flu)/TBI-Based Reduced-Intensity Conditioning (RIC) Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma (NHL) Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (alloHCT). , 2020 .

[13]  B. Scott.  Long-Term Follow up of BMT CTN 0901, a Randomized Phase III Trial Comparing Myeloablative (MAC) to Reduced Intensity Conditioning (RIC) Prior to Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) (MAvRIC Trial) , 2020 .

[14]  M. Biernacki,et al.  Neoantigens in Hematologic Malignancies , 2020, Frontiers in Immunology.

[15]  J. Duffus,et al.  Allogeneic , 2020, Definitions.

[16]  M. Sorror,et al.  Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. , 2019, Blood advances.

[17]  G. Mufti,et al.  Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years. , 2019, Blood advances.

[18]  B. Miller,et al.  The Alpha Emitter Astatine-211 Targeted to CD38 can Eradicate Multiple Myeloma in a Disseminated Disease Model. , 2019, Blood.

[19]  Shunqing Wang,et al.  Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study , 2019, Journal of Hematology & Oncology.

[20]  M. Maris,et al.  Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. , 2019, The Lancet. Haematology.

[21]  P. Hari,et al.  Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience , 2019, Bone Marrow Transplantation.

[22]  H. Deeg,et al.  Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. , 2019, Blood.

[23]  M. Levis,et al.  Radius: Midostaurin (mido) Plus Standard of Care (SOC) after Allogeneic Stem Cell Transplant (alloSCT) in Patients (pts) with FLT3-Internal Tandem Duplication (ITD)–Mutated Acute Myeloid Leukemia (AML) , 2019, Biology of Blood and Marrow Transplantation.

[24]  R. Storb,et al.  Allogeneic hematopoietic cell transplantation in the outpatient setting. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  G. Papanicolaou,et al.  Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  H. Deeg,et al.  Allogeneic Hematopoietic Cell Transplantation in Patients aged 50 years or older with Severe Aplastic Anemia , 2019 .

[27]  J. Ferrara,et al.  GVHD: biology matters. , 2018, Blood advances.

[28]  M. Mohty,et al.  Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis , 2018, Bone Marrow Transplantation.

[29]  H. Einsele,et al.  Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life , 2018, Haematologica.

[30]  P. L. Bergsagel,et al.  Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement , 2018, Bone Marrow Transplantation.

[31]  Michael Boeckh,et al.  Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic‐Cell Transplantation , 2017, The New England journal of medicine.

[32]  R. Storb,et al.  Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. , 2017, Blood advances.

[33]  E. Leifer,et al.  Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Ritz,et al.  Mechanistic approaches for the prevention and treatment of chronic GVHD. , 2017, Blood.

[35]  G. Hill,et al.  Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. , 2017, Blood.

[36]  M. Pasquini,et al.  Current Use and Trends in Hematopoietic Cell Transplantation in the United States. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  R. Vij,et al.  Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML , 2016, Bone Marrow Transplantation.

[38]  S. Heimfeld,et al.  Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GVHD? , 2016, Bone Marrow Transplantation.

[39]  R. Storb,et al.  Nonmyeloablative allogeneic hematopoietic cell transplantation , 2016, Haematologica.

[40]  Y. Kodera,et al.  Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey , 2016, Bone Marrow Transplantation.

[41]  P. Armand,et al.  The addition of sirolimus to the graft‐versus‐host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial , 2016, British journal of haematology.

[42]  A. Barrett,et al.  The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation. , 2015, Annals of translational medicine.

[43]  T. Fleisher.  Transplantation Outcomes for Severe Combined Immunodeficiency 2000–2009 , 2015, Pediatrics.

[44]  Karl Frauendorfer,et al.  One million haemopoietic stem-cell transplants: a retrospective observational study. , 2015, The Lancet. Haematology.

[45]  J. Wagner,et al.  One-unit versus two-unit cord-blood transplantation for hematologic cancers. , 2014, The New England journal of medicine.

[46]  P. Hari,et al.  A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation , 2014, Haematologica.

[47]  M. Sorror,et al.  Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[48]  Loren Gragert,et al.  HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. , 2014, The New England journal of medicine.

[49]  S. Heimfeld,et al.  Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[50]  B. Wood,et al.  A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. , 2014, Cancer research.

[51]  H. Deeg,et al.  Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  M. Schell,et al.  Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization , 2013, Bone Marrow Transplantation.

[53]  Mark Munsell,et al.  Cord-blood engraftment with ex vivo mesenchymal-cell coculture. , 2012, The New England journal of medicine.

[54]  L. Bouzas,et al.  Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[55]  P. Westervelt,et al.  Peripheral-blood stem cells versus bone marrow from unrelated donors. , 2012, The New England journal of medicine.

[56]  J. Beyene,et al.  Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials , 2012, British Journal of Cancer.

[57]  M. K. Kim,et al.  A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome , 2012, Annals of Hematology.

[58]  M. Aljurf,et al.  Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups , 2012, Haematologica.

[59]  R. Storb,et al.  Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. , 2012, Blood.

[60]  B. George,et al.  Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[61]  R. Storb,et al.  90 Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma , 2011 .

[62]  R. Storb,et al.  Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[63]  A. Fischer,et al.  Immune deficiencies , infection , and systemic immune disorders Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe : Entering a new century , do we do better ? , 2010 .

[64]  E. Petersdorf,et al.  The World Marrow Donor Association: Twenty Years of International Collaboration for the Support of Unrelated Donor and Cord Blood Hematopoietic Cell Transplantation , 2010, Bone Marrow Transplantation.

[65]  Colleen Delaney,et al.  Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution , 2010, Nature Medicine.

[66]  R. Storb,et al.  Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. , 2009, Blood.

[67]  R. Storb,et al.  Allogeneic hematopoietic cell transplantation after conditioning with 131 I – anti-CD 45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome , 2009 .

[68]  L. Bouzas,et al.  A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. , 2008, Blood.

[69]  Allen R. Chen,et al.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[70]  H. Einsele,et al.  CMV-specific T cell therapy. , 2008, Blood cells, molecules & diseases.

[71]  L. Leibovici,et al.  Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  M. Maris,et al.  Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2007, Blood.

[73]  J. Klein,et al.  Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. , 2007, Blood.

[74]  D. Hockenbery,et al.  A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. , 2007, Blood.

[75]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[76]  R. Storb,et al.  Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long‐term follow‐up , 2005, British journal of haematology.

[77]  C. Mecucci,et al.  Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  H. Döhner,et al.  Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[79]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[80]  D. Wiley,et al.  Structure of the human class I histocompatibility antigen, HLA-A2. , 2005, Journal of immunology.

[81]  L. Leibovici,et al.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. , 2005, The Cochrane database of systematic reviews.

[82]  É.,et al.  Allogeneic Marrow Grafting for Hematologic Malignancy Using HLA Matched Donor-Recipient Sibling Pairs , 2005 .

[83]  R. Storb,et al.  Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[84]  M. Remberger,et al.  Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. , 2002, Blood.

[85]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[86]  P. Thall,et al.  Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. , 2001, Blood.

[87]  F. Locatelli,et al.  Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. , 2000, Blood.

[88]  S. Saidman,et al.  Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[89]  P. Terasaki,et al.  Origins of the first HLA specificities. , 2000, Human immunology.

[90]  J. Roberts,et al.  Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. , 1999, The New England journal of medicine.

[91]  Anajane G. Smith,et al.  Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. , 1998, Blood.

[92]  M. Boeckh,et al.  Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications , 1998, Clinical Microbiology Reviews.

[93]  H. Deeg,et al.  Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. , 1998, Blood.

[94]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[95]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors , 1997 .

[96]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[97]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.

[98]  A. Nagler,et al.  Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. , 1996, Blood.

[99]  R. Storb,et al.  Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor , 1996, Stem cells.

[100]  Giralt,et al.  Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. , 1995, Blood.

[101]  H. Deeg,et al.  Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. , 1994, Blood.

[102]  S. Y. Yang,et al.  SSOP typing of the Tenth International Histocompatibility Workshop reference cell lines for HLA-C alleles. , 1994, Tissue antigens.

[103]  A. van Leeuwen,et al.  Bone Marrow Donors Worldwide: a successful exercise in international cooperation. , 1994, Bone marrow transplantation.

[104]  H. Deeg,et al.  FK‐506 AND METHOTREXATE PREVENT GRAFT‐VERSUS-HOST DISEASE IN DOGS GIVEN 9.2 Gy TOTAL BODY IRRADIATION AND MARROW GRAFTS FROM UNRELATED DOG LEUKOCYTE ANTIGEN‐NONIDENTICAL DONORS , 1993, Transplantation.

[105]  G. Snell,et al.  The Nobel Lectures in Immunology. Lecture for the Nobel Prize for Physiology or Medicine, 1980: Studies in histocompatibility. , 1992, Scandinavian journal of immunology.

[106]  J. Meyers,et al.  Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. , 1991, The New England journal of medicine.

[107]  F. Appelbaum,et al.  Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. , 1990, Blood.

[108]  R. Storb,et al.  T-cell depletion in allogeneic bone marrow transplantation: progress and problems. , 1989, Haematologica.

[109]  G. Heller,et al.  Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. , 1989, Blood.

[110]  H. Deeg,et al.  Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. , 1988, Blood.

[111]  H. Deeg,et al.  Prednisone and Azathioprine Compared With Prednisone and Placebo for Treatment of Chronic Graft-v-Host Disease : Prognostic Influence of Prolonged Thrombocytopenia After Allogeneic Marrow Transplantation , 2005 .

[112]  MARROW TRANSPLANTATION FOR THALASSAEMIA , 1987, The Lancet.

[113]  H. Deeg,et al.  Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. , 1986, Blood.

[114]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[115]  R. Storb,et al.  Marrow transplantation from related donors other than HLA-identical siblings. , 1985, The New England journal of medicine.

[116]  R. Brookmeyer,et al.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.

[117]  B. Dupont,et al.  Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. , 1983, Blood.

[118]  H. Deeg,et al.  High-dose total-body irradiation and autologous marrow reconstitution in dogs: dose-rate-related acute toxicity and fractionation-dependent long-term survival. , 1981, Radiation research.

[119]  R. Storb,et al.  Specific suppressor cells in graft–host tolerance of HLA-identical marrow transplantation , 1981, Nature.

[120]  O. Laskin,et al.  Acyclovir prophylaxis of herpes-simplex-virus infections. , 1981, The New England journal of medicine.

[121]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[122]  R. Chaganti,et al.  Reconstitution of normal megakaryocytopoiesis and immunologic functions in Wiskott-Aldrich syndrome by marrow transplantation following myeloablation and immunosuppression with busulfan and cyclophosphamide , 1981 .

[123]  K. Sullivan,et al.  Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. , 1981, Blood.

[124]  H. Deeg,et al.  Long-term survival and reversal of iron overload after marrow transplantation in dogs with congenital hemolytic anemia. , 1981, Blood.

[125]  R. Storb,et al.  Transplantation of marrow from an unrelated donor to a patient with acute leukemia. , 1980, The New England journal of medicine.

[126]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[127]  R. Storb,et al.  Marrow grafts between DLA-identical and homozygous unrelated dogs: evidence for an additional locus involved in graft-versus-host disease. , 1977, Transplantation.

[128]  R. Storb,et al.  Demonstration of hemopoietic stem cells in the peripheral blood of baboons by cross circulation. , 1977, Blood.

[129]  R. Storb,et al.  Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. , 1977, The New England journal of medicine.

[130]  R Storb,et al.  Bone-marrow transplantation (second of two parts). , 1975, The New England journal of medicine.

[131]  R Storb,et al.  Bone-marrow transplantation (first of two parts). , 1975, The New England journal of medicine.

[132]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[133]  P. Neiman,et al.  Treatment of established human graft-versus-host disease by antithymocyte globulin. , 1974, Blood.

[134]  R. Storb,et al.  Effect of prior blood transfusions on marrow grafts: abrogation of sensitization by procarbazine and antithymocyte serum. , 1974, Journal of immunology.

[135]  P. Neiman,et al.  Allogeneic marrow grafting for treatment of aplastic anemia. , 1974, Blood.

[136]  A. Rimm,et al.  GRAFT VERSUS LEUKEMIA: III. Apparent Independent Antihost and Antileukemic Activity of Transplanted Immunocompetent Cells , 1973 .

[137]  P. Neiman,et al.  Aplastic anaemia treated by marrow transplantation. , 1972, Lancet.

[138]  R. Storb,et al.  Marrow grafts between canine siblings matched by serotyping and mixed leukocyte culture. , 1971, The Journal of clinical investigation.

[139]  M. Bortin.  A COMPENDIUM OF REPORTED HUMAN BONE MARROW TRANSPLANTS , 1970, Transplantation.

[140]  R. Storb,et al.  METHOTREXATE REGIMENS FOR CONTROL OF GRAFT-VERSUS-HOST DISEASE IN DOGS WITH ALLOGENEIC MARROW GRAFTS , 1970, Transplantation.

[141]  R. Storb,et al.  ALLOGENEIC CANINE BONE MARROW TRANSPLANTATION FOLLOWING CYCLOPHOSPHAMIDE , 1969, Transplantation.

[142]  J. Radl,et al.  Transplantation of bone-marrow cells and fetal thymus in an infant with lymphopenic immunological deficiency. , 1969, Lancet.

[143]  A. Owens,et al.  Allogeneic marrow transplants in cyclophosphamide treated mice. , 1969, Transplantation proceedings.

[144]  R. Gatti,et al.  Immunological reconstitution of sex-linked lymphopenic immunological deficiency. , 1968, Lancet.

[145]  R. Albertini,et al.  Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. , 1968, Lancet.

[146]  R. Storb,et al.  MARROW GRAFTS BY COMBINED MARROW AND LEUKOCYTE INFUSIONS IN UNRELATED DOGS SELECTED BY HISTOCOMPATIBILITY TYPING , 1968, Transplantation.

[147]  R. Storb,et al.  CYTOTOXIC TYPING ANTISERA FOR MARROW GRAFTING IN LITTERMATE DOGS , 1968, Transplantation.

[148]  D. B. Amos,et al.  Hu-1: Major histocompatibility locus in man. , 1967, Science.

[149]  G. Gowland,et al.  Immunological Reactivity of Lymphoid Cells after Treatment with Anti-lymphocytic Serum , 1967, Nature.

[150]  R. Wilson,et al.  Activity of lymphoid tissues from antilymphocyte-serum-treated mice. , 1967, Lancet.

[151]  G. Mathé,et al.  Adoptive immunotherapy of acute leukemia: experimental and clinical results. , 1965, Cancer research.

[152]  P. Terasaki,et al.  Microdroplet Assay of Human Serum Cytotoxins , 1964, Nature.

[153]  E. Thomas,et al.  THE RECOVERY OF LETHALLY IRRADIATED DOGS GIVEN INFUSIONS OF AUTOLOGOUS LEUKOCYTES PRESERVED AT -80 C. , 1964, Blood.

[154]  E. Thomas,et al.  Autografts of bone marrow in dogs after lethal total-body radiation. , 1960, Blood.

[155]  R. Blattner.  Fetomaternal leukocyte incompatibility. , 1959, The Journal of pediatrics.

[156]  D. Uphoff.  Alteration of Homograft Reaction by A-methopterin in Lethally Irradiated Mice Treated with Homologous Marrow , 1958, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[157]  J. Dausset.  Iso-leuco-anticorps , 1958 .

[158]  J. J. Rood,et al.  Leucocyte Antibodies in Sera from Pregnant Women , 1958, Nature.

[159]  E. Thomas,et al.  Successful marrow homograft in the dog after radiation. , 1958, Surgery.

[160]  E. Thomas,et al.  Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. , 1957, The New England journal of medicine.

[161]  J. Loutit,et al.  Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow , 1956, British medical journal.

[162]  R. Prehn,et al.  Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. , 1955, Journal of the National Cancer Institute.

[163]  L. Jacobson.  Evidence for a humoral factor (or factors) concerned in recovery from radiation injury: a review. , 1952, Cancer research.

[164]  E. Shelton,et al.  Modification of irradiation injury in mice and guinea pigs by bone marrow injections. , 1951, Journal of the National Cancer Institute.

[165]  L. Jacobson,et al.  The role of the spleen in radiation injury and recovery. , 1950, The Journal of laboratory and clinical medicine.

[166]  L. Jacobson,et al.  EFFECT OF SPLEEN PROTECTION ON MORTALITY FOLLOWING X-IRRADIATION , 1949 .